Fighting a Global War on Rare Diseases

Are we winning the war against rare, or “orphan,” diseases? A casual observer could be forgiven for thinking so, given the drumroll of news. The crescendo came in 2011, when the U.S. Food & Drug Administration (FDA) approved 26 drugs in this category, meaning for illnesses that afflict fewer than 200,000 people. It was the … Continue reading “Fighting a Global War on Rare Diseases”

Lessons on Bouncing Back From Disaster

Disaster is defined by Merriam-Webster as a sudden or great misfortune or failure. In 2006, NPS Pharmaceuticals had certainly experienced its own “disaster.” With much of the company’s resources dedicated to building a commercial infrastructure in anticipation of FDA approval of its lead product for osteoporosis, the company was thrown a curve ball. NPS received … Continue reading “Lessons on Bouncing Back From Disaster”